TG Therapeutics

TG Therapeutics(TGTX)

NEW YORK, NY
Biotechnology
WebsiteLinkedInCareers Page

Focus: Biologics

TG Therapeutics is a life sciences company focused on Biologics.

OncologyNeurologyUnknownImmunology
Funding Stage
PUBLIC
Open Jobs
15

Products & Portfolio (1)

UKONIQ
umbralisib tosylate
Peak
ORAL · TABLET
2021
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT06143514A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
N/A
No intervention
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT06433765A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
N/A
N/A
Clinical Trials (1)
NCT06864936Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
N/A
N/A
Clinical Trials (1)
NCT06433752A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
N/A
Phase 1
Clinical Trials (1)
NCT03778073Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT02535286Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Phase 1
Ublituximab + TGR-1202
Chronic Lymphocytic Leukemia
Phase 1
Clinical Trials (1)
NCT02006485Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Phase 1
Azercabtagene zapreleucel
B-cell Mediated Autoimmune Disorders
Phase 1
Clinical Trials (1)
NCT06680037A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Phase 1
Phase 1
Clinical Trials (1)
NCT02574663TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT06374173A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
Phase 1
TGR-1202 + brentuximab vedotin
Hodgkin's Lymphoma
Phase 1
Clinical Trials (1)
NCT02164006Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
Phase 1
Phase 1
Clinical Trials (1)
NCT01744912Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase 1
TG-1801
CLL
Phase 1
Clinical Trials (1)
NCT04806035Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1
Phase 1
Clinical Trials (1)
NCT01767766Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT07376707A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Phase 1
NM1F Injection
Ovarian Cancer
Phase 1
Clinical Trials (1)
NCT05746897A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Phase 1
TGR-1202 + Obinutuzumab + Chlorambucil
Chronic Lymphocytic Leukemia
Phase 1
Clinical Trials (1)
NCT02100852TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 1
Phase 1
Clinical Trials (1)
NCT02268851A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Phase 1
Phase 1
Clinical Trials (1)
NCT03671590Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT03804996Study of TG-1801 in Subjects With B-Cell Lymphoma
Phase 1
Phase 1/2
Clinical Trials (1)
NCT02013128Ublituximab + Ibrutinib in Select B-cell Malignancies
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03379051Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01647971Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1/2
Pembrolizumab
Hodgkin's Lymphoma
Phase 2
Clinical Trials (1)
NCT03776864Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2
Phase 2
Clinical Trials (1)
NCT03364231Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Phase 2
Phase 2
Clinical Trials (1)
NCT04149821Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Phase 2
Phase 2
Clinical Trials (1)
NCT04016805Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Phase 2
Phase 2
Phase 2
Clinical Trials (1)
NCT07103746Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Phase 2
Phase 2
Clinical Trials (1)
NCT03828448Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
Phase 2
Phase 2
Clinical Trials (1)
NCT03178201TGR1202 in Relapsed and Refractory Follicular Lymphoma
Phase 2
Phase 2
Clinical Trials (1)
NCT03207256Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Phase 2
Phase 2
Clinical Trials (1)
NCT04163718TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2
Umbralisib
Lymphoma
Phase 2
Clinical Trials (1)
NCT03919175Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Phase 2
Phase 2
Clinical Trials (1)
NCT02738775Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
Phase 2
Phase 2
Clinical Trials (1)
NCT02656303A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
Phase 2
Phase 2
Clinical Trials (1)
NCT02742090Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Phase 2
Phase 2
Clinical Trials (1)
NCT03381170An Extension of the TG1101-RMS201 Trial
Phase 2
Phase 2/3
Clinical Trials (1)
NCT07220252Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT02793583Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT03801525Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Phase 2/3
Phase 3
Clinical Trials (1)
NCT03277248Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Phase 3
Phase 3
Clinical Trials (1)
NCT02301156Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Phase 3
Phase 3
Clinical Trials (1)
NCT05877963Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Phase 3
Phase 3
Clinical Trials (1)
NCT02612311Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Phase 3
Phase 3
Clinical Trials (1)
NCT04130997An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Phase 3
Phase 3
Clinical Trials (1)
NCT07211633A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Phase 3
Phase 3
Clinical Trials (1)
NCT03277261Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
Phase 3
Phase 4
Clinical Trials (1)
NCT07389590Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Phase 4
Phase 4
Clinical Trials (1)
NCT07225361Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Phase 4

Open Jobs (15)

Manager/Director, Payor Analytics

Unknown
2w ago

Study Operations Lead

Unknown
2w ago

Analyst/Manager, Contract Administration

Unknown
2w ago

Accounting Manager, Supply Chain

Unknown
Supply Chain
2w ago

Sr. Statistical Analyst

Unknown
2w ago

Principal Statistical Analyst

Unknown
2w ago

Assoc. Dir/Director, Regulatory CMC

Unknown
Regulatory Affairs
2w ago

Assoc. Director, Key Accounts – Maryland

Maryland
2w ago

Medical Science Liaison, Neurology – Northern, CA

Northern, CA
Medical Affairs
2w ago

Medical Science Liaison, Neurology – Midwest

Midwest
Medical Affairs
2w ago

Director/Sr. Director, R&D Quality

Unknown
Research & Development
2w ago

Manager/Sr. Manager, R&D Quality

Unknown
Research & Development
2w ago

Assoc. Director, Key Accounts – Boston

Boston, MA
2w ago

Director, Internal Controls and SOX – NYC

New York, NY
2w ago

Associate Sales Representative

Unknown
Commercial
2w ago
Interview Prep Quick Facts
Portfolio: 1 approved product, 49 clinical trials
Top TAs: Oncology, Neurology, Immunology
SEC Filings: 2 available
Open Roles: 15 active jobs
Portfolio Health
Peak1 (100%)
1 total products
Therapeutic Area Focus
Oncology
24 pipeline
Neurology
11 pipeline
Immunology
1 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$234M8290%
R&D Spend
$76M(33%)39%
Net Income
$13M
Cash
$93M
Source: SEC 10-K Filing